BGMD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BGMD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
BG Medicine's change in receivables for the quarter that ended in Dec. 2015 was $-0.03 Mil. It means BG Medicine's Accounts Receivable increased by $0.03 Mil from Sep. 2015 to Dec. 2015 .
BG Medicine's change in receivables for the fiscal year that ended in Dec. 2015 was $-0.16 Mil. It means BG Medicine's Accounts Receivable increased by $0.16 Mil from Dec. 2014 to Dec. 2015 .
BG Medicine's Accounts Receivable for the quarter that ended in Dec. 2015 was $0.18 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. BG Medicine's Days Sales Outstanding for the three months ended in Dec. 2015 was 56.95.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. BG Medicine's liquidation value for the three months ended in Dec. 2015 was $-2.38 Mil.
The historical data trend for BG Medicine's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BG Medicine Annual Data | |||||||||||||||||||||
Trend | Dec05 | Dec06 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | |||||||||||
Change In Receivables | Get a 7-Day Free Trial | 0.67 | -0.28 | 0.08 | 0.15 | -0.16 |
BG Medicine Quarterly Data | ||||||||||||||||||||
Mar11 | Jun11 | Sep11 | Dec11 | Mar12 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | |
Change In Receivables | Get a 7-Day Free Trial | 0.08 | 0.04 | -0.27 | 0.10 | -0.03 |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BG Medicine (OTCPK:BGMD) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
BG Medicine's Days Sales Outstanding for the quarter that ended in Dec. 2015 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0.181 | / | 0.29 | * | 91 |
= | 56.95 |
2. In Ben Graham's calculation of liquidation value, BG Medicine's accounts receivable are only considered to be worth 75% of book value:
BG Medicine's liquidation value for the quarter that ended in Dec. 2015 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 1.525 | - | 4.109 | + | 0.75 * 0.181 | + | 0.5 * 0.145 |
= | -2.38 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of BG Medicine's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffrey R Luber | director | 100 CAMPUS DRIVE, C/O EXACT SCIENCES CORP, MARLBOROUGH MA 01752 |
Noubar Afeyan | director, 10 percent owner | C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142 |
Stelios Papadopoulos | director | 3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020 |
Harry W Wilcox | director | ONE KENDALL SQ, BLDG 700, CAMBRIDGE MA 02139 |
Agtc Partners, L.p. | 10 percent owner | C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142 |
Newcogen Group, Inc. | 10 percent owner | C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142 |
Applied Genomic Technology Capital Fund Lp | 10 percent owner | C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142 |
Flagship Pioneering Inc. | 10 percent owner | 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142 |
Agtc Advisors Fund Lp | 10 percent owner | ONE MEMORIAL DRIVE 7TH FLOOR CAMBRIDGE MA 02142 |
Kania Edwin M Jr | 10 percent owner | |
Flagship Ventures Fund 2007, L.p. | 10 percent owner | 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142 |
Flagship Ventures 2007 General Partner Llc | 10 percent owner | 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142 |
Brian S Posner | director | 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
Stephane Bancel | director | 320 BENT STREET, CAMBRIDGE MA 02141 |
Harris Timothy J.r. | director | C/O BG MEDICINE, 610 LINCOLN STREET NORTH, WALTHAM MA 02451 |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.